(Updated - February 29, 2016 8:24 AM EST)

RBC Capital downgraded Orexigen Therapeutics (NASDAQ: OREX) from Outperform to Sector ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change Downgrades Hot Comments

Piper Jaffray Cuts Price Target on Orexigen Therapeutics (OREX) to $5 Following 4Q Results February 29, 2016 8:13 AM Orexigen Therapeutics (OREX) Misses Q4 EPS by 4cFebruary 26, 2016 7:03 AM Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2015February 26, 2016 7:00 AM